// App-Quantinova.ai

: Hypofractionated Radiotherapy for Resectable Pancreatic Ductal Adenocarcinoma: A World First in Response to COVID19

Researchers

Presenter

  • H.V. Spiers

Principal Investigators

  • S.-S. Liau

Medical Centers

  • Addenbrooke's Hospital, Department of Hepato-pancreato-biliary Surgery, Cambridge, United Kingdom

  • University of Cambridge, Department of Oncology, Cambridge, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Pancreas ductal adenocarcinoma

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved